<DOC>
	<DOCNO>NCT01479088</DOCNO>
	<brief_summary>Twelve-month , multicenter , intra-subject control ( retrospective-prospective ) , open-label , active-treatment study evaluate dose-response pharmacokinetics ( PK ) cinacalcet HCl treatment Secondary Hyperparathyroidism ( SHPT ) paediatric subject chronic kidney disease ( CKD ) dialysis , follow 12-month study extension .</brief_summary>
	<brief_title>Cinacalcet Paediatric Secondary Hyperparathyroidism ( SHPT ) Due Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>This multicenter , intra-subject control , open-label , active-treatment study assess child affect Secondary Hyperparathyroidism , age 2-18 year chronic dialysis responsive standard care ( SoC ) therapy , response 6-month cinacalcet compare intra-subject SoC alone screen visit 6 month prior cinacalcet start . Secondary objective evaluate effect growth 18 month PK profile . At baseline child PTH level &gt; 300 pg/mL , plasma P &lt; 6 mg/dL , Ca 8.4-10.5 mg/dL , Ca x P product &gt; 60 responsive SoC . Initial dose cinacalcet 0.5-0.75 mg/Kg per o OD adjust max 180mg OD target PTH value &lt; 180 pg/mL absence hypocalcemia . Thirty child enrol 12 centre participate national paediatric dialysis registry , correspond α=0.05 power 80 % use McNemar test , expect % responder cinacalcet SoC 40 % 5 % respectively , drop-out rate 15 . Primary study endpoint ( EP ) % child reduction baseline &gt; 25 % mean PTH level 6-mo efficacy-assessment period . Among secondary EPs 18 mo % patient mean PTH level &lt; 300 pg/mL ; % change PTH , Ca , P value , Ca x P product ; PK profile ( population profile age ) correlation PTH testosterone level ; auxological index growth velocity ; % child treatment-emergent adverse event lab abnormality ; retention treatment reason treatment withdrawal . The study evaluate whether cinacalcet represent safe effective therapeutic option SHPT child .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Parents'/guardian write informed consent , child 's assent Age &gt; 2 &lt; 18 year ; A dry body weight ( BW ) &gt; 10.49 Kg male &gt; 9.95 Kg female , respectively ; Inpatient outpatient status time enrolment ; Males female . Female subject sexually active must neither pregnant breastfeeding , must lack childbearing potential screening visit end safety followup On stable hemodialysis ( HD ) peritoneal dialysis ( PD ) CKD least one month enter 6month pretreatment period ; Plasma iPTH level &gt; 300 pg/mL , AND Plasma Ca level &gt; 9.4 mg/dL ( normal serum albumin level ) , AND Plasma P level &lt; 6.5 mg/dL patient young 6 year , &lt; 6.0mg/dL old patient , OR Ca x P product &gt; 60 ; Records ' availability follow parameter 6 month prior study entry : demographic information , physical examination , height dry weight , auxological/anthropometric index , blood pressure value , Kt/V urea , plasma iPTH , calcium , phosphorus , alkaline phosphatise level , blood pH bicarbonate , serum creatinine/urea , C reactive protein ( CRP ) level , liver function test , blood count , blood 25 ( OH ) vitamin D3 level . The following laboratory value : Hb &lt; 9.0 g/dL , WBC &lt; 2000/mm3 ( 2x109/L ) , platelets &lt; 150,000/mm3 ( 150x109/L ) subject otherwise eligible PK/PD assessment ; abnormal liver function , define total bilirubin ≥2 time upper limit normal value , ASAT , ALAT , γGT level ≥2 time ULN value . Any lab value opinion investigator might place subject unacceptable risk participation study . History malignancy ( active malignancy , therapy since less 1 year ) History diseases cause hypercalcemia Chronic inflammatory disease ( CReactive ProteinCRP &gt; 2 time upper limit normal value ) require concomitant corticosteroid immunosuppressive therapy History infectious disease ( include opportunistic infection ) within 4 week prior study entry Evidence assess Investigator active latent bacterial , viral fungal infection time potential enrollment , include subject evidence HIV infection . HepatitisB surface antigenpositive subject subject otherwise eligible PK/PD assessment Hepatitis C antibodypositive subject also PCRpositive RIBA positive subject otherwise eligible PK/PD assessment Use recombinant human growth hormone therapy Use drug interact cinacalcet disposition Previous use cinacalcet</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Cinacalcet</keyword>
	<keyword>PK</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Paediatric</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
</DOC>